Literature DB >> 32515023

A call for the appropriate application of clinical pharmacological principles in the search for safe and efficacious COVID-19 (SARS-COV-2) treatments.

Emma H Baker1,2, Danijela Gnjidic3,4, Carl M J Kirkpatrick4,5, Munir Pirmohamed2,6, Daniel F B Wright4,7, Anna Y Zecharia2.   

Abstract

Entities:  

Year:  2020        PMID： 32515023     DOI： 10.1111/bcp.14416

Source DB:  PubMed          Journal:  Br J Clin Pharmacol        ISSN： 0306-5251            Impact factor:   4.335


× No keyword cloud information.
  12 in total

1.  Buying time: Drug repurposing to treat the host in COVID-19H.

Authors:  Jennifer H Martin; Julian Clark; Richard Head
Journal:  Pharmacol Res Perspect       Date:  2020-08

2.  Model-informed drug repurposing: A pharmacometric approach to novel pathogen preparedness, response and retrospection.

Authors:  Michael Dodds; Yuan Xiong; Samer Mouksassi; Carl M Kirkpatrick; Katrina Hui; Eileen Doyle; Kashyap Patel; Eugène Cox; David Wesche; Fran Brown; Craig R Rayner
Journal:  Br J Clin Pharmacol       Date:  2021-02-23       Impact factor: 3.716

Review 3.  Model-Informed Drug Development for Anti-Infectives: State of the Art and Future.

Authors:  Craig R Rayner; Patrick F Smith; David Andes; Kayla Andrews; Hartmut Derendorf; Lena E Friberg; Debra Hanna; Alex Lepak; Edward Mills; Thomas M Polasek; Jason A Roberts; Virna Schuck; Mark J Shelton; David Wesche; Karen Rowland-Yeo
Journal:  Clin Pharmacol Ther       Date:  2021-03-09       Impact factor: 6.875

4.  Preclinical and randomized phase I studies of plitidepsin in adults hospitalized with COVID-19.

Authors:  Jose F Varona; Pedro Landete; Jose A Lopez-Martin; Vicente Estrada; Roger Paredes; Pablo Guisado-Vasco; Lucia Fernandez de Orueta; Miguel Torralba; Jesus Fortun; Roberto Vates; Jose Barberan; Bonaventura Clotet; Julio Ancochea; Daniel Carnevali; Noemi Cabello; Lourdes Porras; Paloma Gijon; Alfonso Monereo; Daniel Abad; Sonia Zuñiga; Isabel Sola; Jordi Rodon; Julia Vergara-Alert; Nuria Izquierdo-Useros; Salvador Fudio; Maria Jose Pontes; Beatriz de Rivas; Patricia Giron de Velasco; Antonio Nieto; Javier Gomez; Pablo Aviles; Rubin Lubomirov; Alvaro Belgrano; Belen Sopesen; Kris M White; Romel Rosales; Soner Yildiz; Ann-Kathrin Reuschl; Lucy G Thorne; Clare Jolly; Greg J Towers; Lorena Zuliani-Alvarez; Mehdi Bouhaddou; Kirsten Obernier; Briana L McGovern; M Luis Rodriguez; Luis Enjuanes; Jose M Fernandez-Sousa; Nevan J Krogan; Jose M Jimeno; Adolfo Garcia-Sastre
Journal:  Life Sci Alliance       Date:  2022-01-10

5.  Model-informed drug repurposing: Viral kinetic modelling to prioritize rational drug combinations for COVID-19.

Authors:  Michael G Dodds; Rajesh Krishna; Antonio Goncalves; Craig R Rayner
Journal:  Br J Clin Pharmacol       Date:  2020-08-05       Impact factor: 4.335

Review 6.  Concerns about pharmacokinetic (PK) and pharmacokinetic-pharmacodynamic (PK-PD) studies in the new therapeutic area of COVID-19 infection.

Authors:  Nicolas Venisse; Gilles Peytavin; Stephane Bouchet; Marie-Claude Gagnieu; Rodolphe Garraffo; Romain Guilhaumou; Caroline Solas
Journal:  Antiviral Res       Date:  2020-07-10       Impact factor: 5.970

7.  Critical Need for Implementation of Clinical Pharmacology Principles in Developing Drugs for the Treatment or Prevention of COVID-19.

Authors:  Gina Pastino
Journal:  J Clin Pharmacol       Date:  2020-07-05       Impact factor: 2.860

Review 8.  Clinical Pharmacology Considerations for Developing Small-Molecule Treatments for COVID-19.

Authors:  Priya Brunsdon; Bhawana Saluja; Chandrahas Sahajwalla
Journal:  J Clin Pharmacol       Date:  2020-07-12       Impact factor: 2.860

9.  Chasing COVID-19 chemotherapeutics without putting the cart before the horse.

Authors:  Steven P Rannard; Tom O McDonald; Andrew Owen
Journal:  Br J Clin Pharmacol       Date:  2020-11-20       Impact factor: 3.716

Review 10.  Toward Consensus on Correct Interpretation of Protein Binding in Plasma and Other Biological Matrices for COVID-19 Therapeutic Development.

Authors:  Marta Boffito; David J Back; Charles Flexner; Peter Sjö; Terrence F Blaschke; Peter W Horby; Dario Cattaneo; Edward P Acosta; Peter Anderson; Andrew Owen
Journal:  Clin Pharmacol Ther       Date:  2020-11-21       Impact factor: 6.875
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.